Frédéric Chéreau
Algemeen Directeur bij LOGICBIO THERAPEUTICS, INC.
Actieve functies van Frédéric Chéreau
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
LOGICBIO THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-04-2016 | - |
Algemeen Directeur | 01-04-2016 | - | |
President | 01-04-2016 | - | |
ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-11-2022 | - |
MYOSIX SA
MYOSIX SA BiotechnologyHealth Technology MYOSIX SA develops cell-based therapeutics. The company is involved in the development of autologous cell therapy products for the treatment of cardiopathies and certain forms of myopathy in humans. MYOSIX specializes in the development of cell-based therapeutics against other pathologies like cancers. MYOSIX is also engaged in a number of R&D projects and develops a cell and tissue bank for therapeutic or R&D purposes. The company was founded by Vilquin, Marolleau, Scorsin, Eisenmann and Halioua in 2000 and is headquartered in Saint-Germain-en-Laye, France. | Algemeen Directeur | - | - |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Independent Dir/Board Member | 12-10-2021 | - |
Voorzitter | 20-10-2022 | - | |
Directeur/Bestuurslid | 12-10-2021 | 20-10-2022 | |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | Voorzitter | - | - |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Directeur/Bestuurslid | 01-01-2017 | - |
Loopbaan van Frédéric Chéreau
Eerdere bekende functies van Frédéric Chéreau
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ATYR PHARMA, INC. | Operationeel Directeur | 05-02-2014 | 13-07-2015 |
President | 05-02-2014 | 13-07-2015 | |
French American Chamber of Commerce New England | Directeur/Bestuurslid | 01-01-2008 | 01-01-2014 |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Corporate Officer/Principal | 26-09-2012 | 01-12-2013 |
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - | |
░░░░░░░░░ | - | - |
Opleiding van Frédéric Chéreau
INSEAD | Masters Business Admin |
Université Paris 1 Panthéon-Sorbonne | Undergraduate Degree |
Groupe de Sup de Co La Rochelle | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 11 |
Frankrijk | 8 |
Operationeel
Director/Board Member | 5 |
Corporate Officer/Principal | 4 |
Chief Executive Officer | 3 |
Sectoraal
Health Technology | 11 |
Consumer Services | 4 |
Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ATYR PHARMA, INC. | Health Technology |
Bedrijven in privébezit | 13 |
---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Pervasis Therapeutics, Inc.
Pervasis Therapeutics, Inc. Medical SpecialtiesHealth Technology Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. The company was founded by Robert S. Langer Jr. and Helen Marie Nugent in 2004 and is headquartered in Waltham, MA. | Health Technology |
MYOSIX SA
MYOSIX SA BiotechnologyHealth Technology MYOSIX SA develops cell-based therapeutics. The company is involved in the development of autologous cell therapy products for the treatment of cardiopathies and certain forms of myopathy in humans. MYOSIX specializes in the development of cell-based therapeutics against other pathologies like cancers. MYOSIX is also engaged in a number of R&D projects and develops a cell and tissue bank for therapeutic or R&D purposes. The company was founded by Vilquin, Marolleau, Scorsin, Eisenmann and Halioua in 2000 and is headquartered in Saint-Germain-en-Laye, France. | Health Technology |
MG Biotherapeutics LLC | |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Syndexa Pharmaceuticals Corp.
Syndexa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Syndexa Pharmaceuticals Corp. developed novel medicines for the treatment and prevention of metabolic diseases. The company was founded in 2005 and was headquartered in Watertown, MA. | Health Technology |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | Finance |
LogicBio Therapeutics, Inc.
LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Health Technology |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Health Services |
French American Chamber of Commerce New England |
- Beurs
- Insiders
- Frédéric Chéreau
- Ervaring